Skip to main content

Table 3 Univariate and multivariate analysis of factors associated with outcome, stratified by cancer type*

From: Role of chest CT scan in patients with preexisting cancer and COVID-19 pneumonia

All cancer

Gastrointestinal

Hematologic

Variable

Dead/alive

OR1

OR2

Dead/alive

OR2

Dead/alive

OR2

RSNA classification

 Negative

6/32

Ref

Ref

5/6

Ref

1/12

Ref

 Atypical

20/38

2.80 (1.005–7.83)

2.44 (0.85–6.98)

7/10

0.73 (0.14–3.77)

5/5

11.47 (0.89–147.18)

 Indeterminate

17/39

2.32 (0.82–6.58)

2.24 (0.78–6.43)

8/9

1.12 (0.22–5.61)

4/10

4.21 (0.37–47.52)

 Typical

45/69

3.47 (1.34–8.98)

2.99 (1.14–7.86)

17/16

1.39 (0.31–6.17)

9/24

2.28 (0.21–24.26)

CT score

 0

26/69

Ref

Ref

12/16

Ref

6/17

Ref

 ≤ 18

7/32

0.58 (0.22–1.47)

0.59 (0.23–1.53)

2/7

0.47 (0.07–2.91)

4/9

1.10 (0.22–5.49)

 > 18

55/77

1.89 (1.07–3.34)

1.81 (1.01–3.23)

23/18

1.94 (0.69–5.45)

9/25

0.53 (0.13–2.16)

Pattern of involvement

 Normal

26/69

Ref

Ref

12/16

Ref

6/17

Ref

 Pure GGO

14/38

0.99 (0.46–2.12)

0.88 (0 .40–1.93)

4/10

0.48 (0.11–2.17)

4/14

0.51 (0.10–2.55)

 Mixed GGO and consolidation

48/70

1.84 (1.03–3.30)

1.86 (1.03–3.36)

21/15

2.40 (0.81–7.11)

9/20

0.79 (0.20–3.07)

 Predominant GGO

41/65

1.69 (0.93–3.08)

1.68 (0.91–3.09)

19/14

2.34 (0.77–7.06)

8/19

0.70 (0.17–2.86)

 Predominant consolidation

7/5

3.76 (1.09–12.9)

4.55 (1.28–16.17)

2/1

3.17 (0.23–42.3)

1/1

2.29 (0.11–45.14)

Other abnormality

 Crazy paving

16/23

1.49 (0.74–3.00)

1.36 (0.66–2.80)

6/5

1.51 (0.39–5.78)

3/6

0.72 (0.13–3.93)

 Pleural effusion

43/46

2.74 (1.60–4.68)

2.94 (1.69–5.12)

17/11

2.52 (0.93–6.85)

8/8

5.34 (1.36–20.90)

 Pericardial effusion

5/6

1.72 (0.51–5.82)

1.75 (0.50–6.06)

1/2

0.93 (0.07–11.52)

1/2

1.20 (0.08–16.27)

 Lymphadenopathy

8/25

0.61 (0.26–1.41)

0.58 (0.25–1.37)

2/4

0.54 (0.09–3.29)

3/7

0.92 (0.20–4.28)

 Centrilobular nodules

14/13

2.40 (1.07–5.36)

2.89 (1.25–6.65)

7/1

16.88 (1.71–166.38)

2/3

2.55 (0.32–19.99)

 Mass

7/7

2.11 (0.71–6.21)

2.18 (0.72–6.59)

1/0

-

2/2

5.68 (0.54–59.19)

 Architectural distortion

13/9

3.25 (1.33–7.94)

3.76 (1.50–9.40)

6/2

7.13 (1.19–42.74)

3/1

10.53 (0.94–117.32)

 Nodular metastatic

10/12

1.77 (0.73–4.28)

1.72 (0.70–4.24)

4/2

2.40 (0.37–15.50)

1/1

5.40 (0.20–140.97)

  1. Bold numbers are indicative of significant OR with P-value < 0.05
  2. *Breast and other cancer not shown in this table because there is no significance in the analysis
  3. OR2 = adjusted by age, gender, comorbidities